A common barrier to implementing TDM is third-party payers denials to cover testing (21), despite the growing number of publications describing the clinical benefit and cost-effectiveness of TDM, specifically for anti-TNF-α therapy in IBD. This evidence concerns the gene TNF and inflammatory bowel disease.